1. Introduction {#s0005}
===============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which was for the first time met in China in the end of the year 2019 (Zhu et al., 2020). After that, the virus has caused a severe pandemic (Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, 2020). The acute COVID-19 is diagnosed by nucleic acid amplification test (NAAT). SARS-CoV-2 antibodies are formed in the blood usually within 2--3 weeks after infection (Okba et al. 2020), and their determination can be used in epidemiological surveys and as a support in the diagnostics of prolonged and obscure cases. However, CE marked, in vitro diagnostics (IVD) suitable and US Food and Drug Administration (FDA) Emergency Use Authorized (EUA) SARS-CoV-2 antibody tests have not come on the market until recently, and there exists a few articles on the performance of fully automated test platforms (Egger et al., 2020; Kohmer et al., 2020; Merrill et al. 2020; Montesinos et al., 2020; Plebani et al. 2020a; Tang et al. 2020a; Tang et al. 2020b; Tré-Hardy et al. 2020). In this paper, we compared the performance of the fully automated Elecsys® Anti-SARS-CoV-2 test detecting antibodies against nucleocapsid N protein and LIAISON® SARS-CoV-2 S1/S2 IgG test detecting antibodies against spike protein S1- and S2-antigens.

2. Materials and methods {#s0010}
========================

*2.1 Evaluation samples*

The seroconversion panel part of the study comprised of 120 samples from 13 patients \[age 55 years (median), range 20--79; 8 males\], of whom the seroconversion time was sought. The patients had been admitted to Tampere University Hospital or other communal hospitals in Fimlab Laboratories operation region due to aggravated COVID-19 respiratory tract symptoms i.e. difficulty breathing with positive NAAT result. During hospitalization, blood cell count from EDTA blood was analyzed from the patients almost daily. After this routine analysis, the residual samples were collected from these patients, and the EDTA plasma was separated and stored −20 °C until the evaluation.

The other part of the study concerning sensitivity and specificity of the tests was partly based on the seroconversion panel \[n = 5, age 55 years (median), range 34--79; 2 males\], but also residual plasma/serum samples from the COVID-19 NAAT positive outpatients were traced and collected for evaluation \[n = 35, age 47 years (median), range 11--95; 12 males\]. All these patients had had respiratory tract symptoms including rhinitis, cough, sore throat, chest pain and/or difficulty breathing, with or without fever. In this part, the follow-up time after positive NAAT result was at least 16 days. The control material comprised of 161 serum samples from apparently healthy adults \[age 45 years (mean), range 32--65; 72 males\] with mildly-to-moderately increased total cholesterol taken part in the chitosan study before the COVID-19 era (Lehtimäki et al., 2005). These samples had been stored −20 °C before the comparison. The use of these samples for control purposes had an approval from The Ethics Committee of the Tampere University Hospital District, and all participants had given their written informed consent.

For the detection of possible cross-reactions in the tests, follow-up plasma/serum samples from other coronavirus and influenza A/B PCR positive patients, and serum/plasma samples from acute Epstein--Barr virus (EBV: IgG VCA and IgM antibodies positive, and IgG EBNA antibodies negative), hepatitis B core antibody (HBcAb), anti-nuclear antibody (ANA) and rheumatoid factor (RF) positive patients were included in the study material (n = 43). EBV, HBcAb and ANA positive samples had been collected in year 2019 and RF positive samples in year 2017 before the COVID-19 pandemic. The samples from other coronavirus and influenza A/B patients had been collected in April--May, 2020.

*2.2. Methods*

SARS-CoV-2 antibodies were analyzed using Elecsys® Anti-SARS-CoV-2 test (Roche Diagnostics GmbH, Mannheim, Germany) detecting the antibodies against nucleocapsid N protein, and LIAISON® SARS-CoV-2 S1/S2 IgG test (DiaSorin S.p.A., Saluggia, Italy) detecting the antibodies against spike (S) protein S1- and S2-antigens. Primary COVID-19 diagnosis had been based on in-house real time RT-PCR test detecting E-gene target sequence according to Corman (Corman et al., 2020), Allplex™ 2019-nCoV Assay (Seegene Inc., Seoul, South Korea) detecting target sequences E, N and RdRp, or Abbott RealTi*m*e SARS-CoV-2 Assay (Abbott Laboratories, Illinois, U.S.A) detecting target sequences N and RdRp. The used RT-PCR method had been chosen based on the availability. The primary COVID-19 diagnosis was based on one RT-PCR result. All the serologically discrepant cases had been tested with at least one of the available commercial RT-PCR tests detecting several viral domains.

3. Results and discussion {#s0015}
=========================

The antibody kinetics of the patients in the seroconversion panel is illustrated in [Fig. 1](#f0005){ref-type="fig"} . and the seroconversion times in [Fig. 2](#f0010){ref-type="fig"} . The time interval from the positive NAAT result to seroconversion was 5 days (median, range 0--11 days) with Elecsys® and 7 days (median, range 2--13 days) with LIAISON®. The seroconversion was first detected with Elecsys® in ten and with LIAISON® in two patients, and at the same time in one patient. In both methods, the seroconversion had happened in 85% (11/13) of the patients within 8 days and in all within 13 days after the positive NAAT result. The time interval from the onset of symptoms to seroconversion was 11 days with Elecsys® (median, range 7--17 days) and 12 days (median, range 8--21) with LIAISON®, respectively. Although in some studies a decline in SARS-CoV-2 antibodies has been detected a few weeks after seroconversion (Favresse et al. 2020a: Seow et al. 2020), in our seroconversion panel the antibody trend was rising in all patients with both methods. However, the follow-up time was quite short.Fig. 1The SARS-CoV-2 antibody kinetics in COVID-19 patients determined by Elecsys® Anti-SARS-CoV-2 and LIAISON® SARS-CoV-2 S1/S2 IgG tests. The analyses were carried out of 83 samples in the seroconversion panel.Fig. 1Fig. 2SARS-CoV-2 antibody seroconversion time in COVID-19 patients determined by Elecsys® Anti-SARS-CoV-2 and LIAISON® SARS-CoV-2 S1/S2 IgG tests. Antibody level of the first positive sample (COI for Elecsys® and AU/mL for LIAISON®) in shown in the bar. The cut-off values for the positive result are ≥1 COI and ≥ 15 AU/mL.Fig. 2

Elecsys® detects total antibodies against N protein, while LIAISON® detects only IgG antibodies against S1 and S2 antigens. The S protein is an immunogenic surface structure of the SARS-CoV-2 involved in the virus attachment to the host cells, and its functional subunits (S1 and S2) are used in the immunoassays. N protein is, in turn, the major structural protein of the SARS-CoV-2 involved in the replication processes of the virus (Infantino et al., 2020). The positive antibody test result refers to that the person has had COVID-19, but it does not definitely tell about protective immune response. N protein based tests may be more sensitive to detect past COVID-19, but S protein may be a possible target for neutralizing antibodies, and SARS-CoV-2 antibodies against that antigen may better predict the protective immunity (Walls et al. 2020). It has been suggested that the immune response against S antigens might become earlier than against N antigen (Liu et al., 2020). However, in some clinical test comparisons the observed seroconversion time has been shorter with the tests detecting total antibodies to N antigen compared to those detecting IgG antibodies to S antigens, though the studies using systematic seroconversion panels with follow-up samples are sparse (Montesinos et al., 2020; Tang et al. 2020a). In our seroconversion panel, the first positive result was detected in most cases earlier with Elecsys® using N antigen than with LIAISON® using S1/S2 antigens. Since it has been shown that SARS-CoV-2 IgG and IgM antibodies can occur simultaneously or sequentially either IgG or IgM first (Long et al., 2020), it can be speculated whether the IgM in the Elecsys® total antibody composition causes the earlier positive reaction in some cases compared to LIAISON®. However, it is also possible that it is a result of differences in the test chemistry or the antibody response to different antigens (Long et al., 2020; Tang et al. 2020b). The seroconversion times with Elecsys® and LIAISON® in our study were well in line with the other studies (Okba et al. 2020; Egger et al., 2020).

Sensitivity and specificity of the tests are shown in [Table 1](#t0005){ref-type="table"} . The sensitivity and specificity of the Elecsys® were 92.5% and 98.8% and of LIAISON® 87.5% and 97.5%, respectively. The positive (PPV) and negative (NPV) predictive values with different assumed COVID-19 prevalence in the population are shown in the table. Elecsys® seemed to be more sensitive and specific than LIAISON®, but the differences were minor and the number of tested samples was limited. In the study by Egger et al., the sensitivity and specificity of the Elecsys® were 100% and 99.8 in the samples taken over 15 days after symptom onset, respectively, but the number of COVID-19 positive cases in that time point was only 18 (Egger et al., 2020). In the study by Favresse et al. (2020b), the specificity of the Elecsys® was 100% and the sensitivity over 90% in the samples taken after 14 days after positive NAAT or symptom onset, and the results were also in line with Tang et al. (2020b). According to the study by Tre-Hardy et al., the sensitivity and specificity of the LIAISON® test was 91% and 100%, respectively, evaluated from the samples taken 2 weeks after the positive NAAT result (Tré-Hardy et al. 2020). The results were quite similar in the study by Plebani et al. (2020a), in which the samples were collected over 12 days after the onset of symptoms. In one comparison of several tests, the Elecsys® and LIAISON® performed quite equally, the sensitivities being 75.6% in both, and specificities 97% and 100%, respectively. However, in that study the time interval after positive NAAT to serological test varied from 2 to 49 days, so some seroconversions had probably not happened yet, and also the control group was quite small consisting of 19 persons (Kohmer et al., 2020). In the study by Merrill et al., Elecsys® seemed to be somewhat more sensitive and specific than LIAISON®, but the sensitivity remained quite low in both methods, since the majority of the test samples was collected within one week after positive NAAT (Merrill et al. 2020).Table 1Sensitivity and specificity of the Elecsys® Anti-SARS-CoV-2 and LIAISON® SARS-CoV-2 S1/S2 IgG tests. The positive (PPV) and negative (NPV) predictive values with different assumed COVID-19 prevalence in the population are shown in the table.Table 1**Test and resultCOVID-19 NAAT test resultSensitivity (%)Specificity (%)PPV (%)**\
**(COVID-19**\
**prevalence 1/5/10%)NPV (%)**\
**(COVID-19**\
**prevalence 1/5/10%)**Positive (n = 40)Negative\
(n = 161)**Elecsys®**\
**Anti-SARS-CoV-2**Positive372^b^92.5\
(CI: 79.6--98.4)98.8\
(CI: 95.6--99.9)42.9/79.7/89.299.9/99.6/99.2Negative3^a^159**LIAISON® SARS-CoV-2 S1/S2 IgG**Positive354^b^87.5\
(CI: 73.2--95.8)97.5\
(CI: 93.8--99.3)26.2/65.0/79.799.9/99.3/98.6Negative5157[^1]

Some research groups have intended to optimize the cut-offs of Elecsys® and LIAISON® tests, and ended up to the levels of 0.165 COI regarding Elecsys® and 6.1--6.2 AU/mL regarding LIAISON®. (Favresse et al. 2020b; Favresse et al. 2020c; Plebani et al. 2020a; Plebani et al. 2020b; Tré-Hardy et al. 2020). We applied also a receiver operating characteristic (ROC) curve performance analysis, and determined the optimal cut-off for the tests in our material using Youden index. The optimal cut-off for Elecsys® was 0.137 COI with the sensitivity and specificity of 97.5% and 96.9%, and for LIAISON® 11.9 AU/mL with the sensitivity and specificity of 90.0% and 96.9%, respectively. According to our results the optimized cuf-off for Elecsys® was well in line with the other studies, but for LIAISON® it was somewhat higher. These optimized cut-offs needs to be validated more and taken into consideration when the serological methods are applied into the clinical use.

SARS-CoV-2 antibodies remained negative in in three NAAT positive COVID-19 patients in both Elecsys® and LIAISON® tests. The follow-up times after positive NAAT were 28, 45 and 53 days, respectively. Plebani et al. have reported of COVID-19 cases that are not able to produce detectable antibodies to N or S antigens (Plebani et al. 2020a). Thus the negative serology does not exclude the possibility of previous COVID-19 infection. Two NAAT positive COVID-19 patients were positive with Elecsys®, but remained negative with LIAISON®. The follow-up times were 34 and 77 days, respectively. From the control sample material collected before COVID-19 era, four samples were positive with LIAISON® and two with Elecsys®. All of the false positive results were from different control samples. Based on our results, the overall specificity of the antibody testing increases reaching 100%, if the positive antibody results are being confirmed with another method. However, if the positive Elecsys® result is confirmed with LIAISON®, the sensitivity decreases. Thus in this sense, to increase the accuracy of the overall testing results and taken also the financial impact into account, the SARS-CoV-2 antibodies should be screened against N antigen (Elecsys®), and reactive samples confirmed with S antigen test (LIAISON®), but the both SARS-CoV-2 antibody test results should be reported parallel for clinical evaluation and related to the patient\'s clinical picture. A paired sample should be taken into consideration if there is a discrepancy within the two results and the time from the onset of symptoms is inadequate.

Cross-reactivities were tested for several conditions as shown in [Table 2](#t0010){ref-type="table"} . Two human coronavirus (HCoV) -OC43 positive patients had also a positive LIAISON® test result 60 and 70 days after HCoV-OC43 diagnosis (levels 19 and 21 AU/mL, respectively). However, antibodies against SARS-CoV-2 N protein by Elecsys® were totally negative (0.076 and 0.084 COI, respectively). Since the samples had been collected in April and May 2020, it is possible that these patients may also have had a non-diagnosed COVID-19 and thus specific SARS-CoV-2 antibodies, but it is unlikely, since the COVID-19 morbidity rates in Finland have so far remained considerably low (134 diagnosed cases/100000 persons until July 31, 2020), and the seroprevalence has been below 0.5% in general population determined by a golden standard method i.e. virus microneutralisation (Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, 2020; Serological population study of the coronavirus epidemic by Finnish Institute for Health and Welfare, 2020). Furthermore, S-protein antibody positivity (LIAISON®) without detectable N protein antibodies (Elecsys®) among the true positive COVID-19 patients seemed to be atypical according our results. Thus the LIAISON® results were estimated to be false positive. Otherwise all the cross-reactivity results were negative. SARS-CoV-2 belongs to Betacoronaviruses like HCoV-OC43 and HCoV-HKU1. HCoV-229E and HCoV-NL63 belong to Alphacoronaviruses. The cross-reactions are usually seen within Alpha- and Betacoronavirus genera but not between them (Huang et al. 2020).Table 2Cross-reactivity testing for Elecsys® Anti-SARS-CoV-2 and LIAISON® SARS-CoV-2 S1/S2 IgG tests against several conditions to evaluate potential interference.Table 2**Possible cross-reactive samplesnDays after positive NAAT to sample collection, median (range)Elecsys® Anti-SARS-CoV-2 positive resultLIAISON® SARS-CoV-2 S1/S2 IgG positive result**Human coronavirus OC43^a^1335 (4--100)02^d^Human coronavirus NL63^a^240 (27--52)00Human coronavirus 229E^a^18200Human coronavirus OC43 and human bocavirus^a^13500Influenza A virus^a^558 (41--85)00Influenza A and B virus^a^15400Acute EBV (IgG VCA and EBNA, and IgM antibodies positive)^b^5-00HBcAb positive^b^5-00ANA positive^b^5-00RF positive^c^5-00[^2]

In this study, we compared the performance of the fully automated Elecsys® Anti-SARS-CoV-2 test detecting antibodies against nucleocapsid N protein and LIAISON® SARS-CoV-2 S1/S2 IgG test detecting antibodies against spike protein S1- and S2-antigens. The seroconversion was detected in most cases earlier with Elecsys® than with LIAISON®, but the antibodies could be quite reliable detected 2 weeks after NAAT positivity and 3 weeks after the symptom onset with both methods. Elecsys® was somewhat more sensitive and specific than LIAISON®, but the differences were minor. However, since some patients were seropositive only with Elecsys®, we conclude that the SARS-CoV-2 antibodies should be screened against N antigen (Elecsys®), and reactive samples confirmed with S antigen test (LIAISON®), but the both test results should be reported parallel for clinical evaluation and related to the patient\'s clinical picture. Furthermore, in some patients the COVID-19 serology may remain completely negative. Because clear guidelines for the use of SARS-CoV-2 serology are lacking at the moment, these aspects should be taken into consideration when these processes are assessed.
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[^1]: NAAT, nucleic acid amplification test; CI, 95% confidence interval; ^a^these samples were also negative with LIAISON®, ^b^all false positive antibody results were obtained from different control samples.

[^2]: NAAT, nucleic acid amplification test, Allplex Respiratory Panel 1 & 3, Seegene; EBV, Epstein--Barr virus; HBcAb, hepatitis B core antibody; ANA, anti-nuclear antibody; RF, rheumatoid factor; ^a^Samples collected in April--May, 2020, ^b^Samples collected in year 2019, ^c^Samples collected in year 2017, ^d^time after diagnosis to sample collection 60 and 70 days, respectively.
